her3-dxd,patritumab
amgen,daiichi sankyo
['patritumab', 'her3-dxd', 'bcsm', 'tnbc', 'rux,(-crux),(-trux)']
her3-dxd in er+/her2- or tnbc
(patritumab deruxtecan) phase ii, 60 pts
60% of patients with 3+ prior regimens
40% tnbc
median tx duration 5.2 mo
orr 35%, responses across her3 expression levels
majority of pts with tumor shrinkage
trials ongoing #asco23 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.